Researchers present results from pivotal cancer trials, including an ADC-Keytruda combination, at the European Society for Medical Oncology Congress on Oct. 22 (Kyle LaHucik for Endpoints News)

October 23, 2023 08:32 AM EDTUpdated 10:59 AM

R&D

In Focus

You get an ADC, you get an ADC: Pharmas bite on oncology’s buzziest class

Lei Lei Wu

News Reporter

Kyle LaHucik

Senior Reporter

MADRID — When Daiichi Sankyo scientists pushed forward with antibody-drug conjugate research nearly a decade ago, the program had a lot of naysayers, even inside the …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

You get an ADC, you get an ADC: Pharmas bite on oncology’s buzziest class

Lei Lei Wu

News Reporter

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

Among pharma CEOs, the IRA now and the IRA later get very different reactions

Bristol Myers restarts radiopharmaceutical Phase 3 trial, but delays readout by one year

Andrew Left, short seller who campaigned against Valeant, is accused of fraud by SEC

Updated: With cost-cutting underway, Bristol Myers raises guidance, touts Phase 3 win and scraps another

Compounded weight loss drugs have resulted in misdosing, hospitalizations, FDA warns

Critical Junctures in Gene Therapy Clinical Material Manufacturing: Where Do I Start? And Will It Work?

You get an ADC, you get an ADC: Phar­mas bite on on­col­o­gy’s buzzi­est class

News Reporter

Senior Reporter

Sign up to read this article for free.

You get an ADC, you get an ADC: Pharmas bite on oncology’s buzziest class